Michael J. Colwill

St George's University Hospitals NHS Foundation Trust
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Unusual mass at the hepatic flexure.

Unusual mass at the hepatic flexure.

Journal: Gut

Published: August 21, 2026

Neonatal Fc receptor (FcRn) inhibition and the implications for inflammatory bowel disease and co-existing immune-mediated diseases.

Neonatal Fc receptor (FcRn) inhibition and the implications for inflammatory bowel disease and co-existing immune-mediated diseases.

Journal: Expert review of gastroenterology & hepatology

Published: August 15, 2026

Anogenital cutaneous Crohn's disease: effective treatment with interleukin-23 p19 inhibition in an under-recognized clinical entity.

Anogenital cutaneous Crohn's disease: effective treatment with interleukin-23 p19 inhibition in an under-recognized clinical entity.

Journal: Journal of Crohn's & colitis

Published: April 26, 2026

Transgender and gender diverse populations: lessons from IBD care.

Transgender and gender diverse populations: lessons from IBD care.

Journal: The lancet. Gastroenterology & hepatology

Published: February 16, 2026

Digital twins in IBD-bridging data, biology and trial innovation.

Digital twins in IBD-bridging data, biology and trial innovation.

Journal: Gut

Published: February 09, 2026

Nomenclature of therapies in inflammatory bowel disease: A journey through time and terminology.

Nomenclature of therapies in inflammatory bowel disease: A journey through time and terminology.

Journal: Inflammatory bowel diseases

Published: November 05, 2025

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential.

Glucagon-like peptide-1 (GLP-1) receptor agonists in inflammatory bowel disease: mechanisms, clinical implications, and therapeutic potential.

Journal: Journal of Crohn's & colitis

Published: September 19, 2025

Sphingosine-1-Phosphate (S1P) Receptor Modulators for the Treatment of Inflammatory Bowel Disease (IBD): Mechanisms, Clinical Evidence, and Practical Insights.

Sphingosine-1-Phosphate (S1P) Receptor Modulators for the Treatment of Inflammatory Bowel Disease (IBD): Mechanisms, Clinical Evidence, and Practical Insights.

Journal: Biomedicines

Published: August 20, 2025

Optimising Monoclonal Antibody Drug Development for Inflammatory Bowel Disease.

Optimising Monoclonal Antibody Drug Development for Inflammatory Bowel Disease.

Journal: Clinical and experimental gastroenterology

Published: June 09, 2025

Risankizumab is effective following ustekinumab failure in Crohn's disease: A real-world study from a tertiary center.

Risankizumab is effective following ustekinumab failure in Crohn's disease: A real-world study from a tertiary center.

Journal: World journal of gastrointestinal pharmacology and therapeutics

Published: June 03, 2025

The impact of ethnicity on delays in initiating advanced therapy for inflammatory bowel disease.

The impact of ethnicity on delays in initiating advanced therapy for inflammatory bowel disease.

Journal: European journal of gastroenterology & hepatology

Published: May 13, 2025

Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis.

Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: January 15, 2025

Showing 1-12 of 27

Last Updated: 09/26/2026